Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

Sponsor
The First Affiliated Hospital of Dalian Medical University
Study ID
NCT05418465
Status
Unknown

Conditions

  • Diabetic Nephropathies

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Huangqi Guizhi Wuwu decoction — DRUG
    Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
  • Dapagliflozin — DRUG
    Dapagliflozin, 10mg at a time, once a day. Oral administration.

Study Details

This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.

Key Dates

First listed
Jun 14, 2022
Start date
Jan 26, 2022
Status verified
Jun 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Huangqi Guizhi Wuwu decoction group
    Huangqi Guizhi Wuwu decoction
  • Active Comparator: Dapagliflozin group
    Dapagliflozin

Primary Outcome Measure

Rate of change in Estimated Glomerular Filtration Rate (eGFR) compared to baseline [ Time Frame: 12 weeks ]

Related Studies